Antimicrobial Resistance Market By Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), By Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus

Antimicrobial Resistance Market By Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), By Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, Others), By Indication (Complicated Urinary Tract Infections (cUTI), Blood stream infections, Acute bacterial skin and skin structure infections (ABSSSI), Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), Community acquired pneumonia (CAP), Others), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


The antimicrobial resistance market was valued at $4.6 billion in 2022 and is estimated to reach $9.5 billion by 2032, exhibiting a CAGR of 7.6% from 2023 to 2032. Antimicrobial resistance (AMR), also known as drug resistance is the resistance developed by the bacteria, viruses, fungi, and parasites to the available antimicrobial drugs over a period. It is a comprehensive concept and often encompasses resistance to antibacterial, antiviral, antiparasitic, and antifungal drugs. The microorganisms which become resistant to most of the antimicrobials are often referred to as superbugs. Few examples of superbugs include MRSA (methicillin-resistant staphylococcus aureus), Clostridium difficile (C. diff), and the bacteria that cause multi-drug-resistant tuberculosis.

Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.

Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.

In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.

Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.

On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.

However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.

The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.

On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

Complicated Urinary Tract Infections (cUTI)
Blood stream infections
Acute bacterial skin and skin structure infections (ABSSSI)
Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
Community acquired pneumonia (CAP)
Others

By Drug Class

Combination therapies
Tetracyclines
Cephalosporins
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Others

By Mechanism of Action

Protein Synthesis Inhibitors
Cell Wall Synthesis Inhibitors
Others

By Pathogen

Klebsiella pneumoniae
Pseudomonas aeruginosa
Staphylococcus aureus
Enterococcus Spp
Others
Escherichia coli

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Cumberland Pharmaceuticals
Acurx Pharmaceuticals, Inc.
Paratek Pharmaceuticals Inc
Alkem Laboratories Ltd.
Nabriva Therapeutics plc
Innoviva, Inc
Basilea Pharmaceutica Ltd
Wockhardt Limited.
Merck & Co., Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Overuse and misuse of antibiotics
3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections
3.4.1.3. Growth in burden of antimicrobial resistance
3.4.2. Restraints
3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance
3.4.3. Opportunities
3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally
CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Combination therapies
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Tetracyclines
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cephalosporins
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Glycopeptides and Lipoglycopeptides
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Oxazolidinones
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. Others
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN
5.1. Overview
5.1.1. Market size and forecast
5.2. Escherichia coli
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Klebsiella pneumoniae
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Pseudomonas aeruginosa
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Staphylococcus aureus
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Enterococcus Spp
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Complicated Urinary Tract Infections (cUTI)
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Blood stream infections
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Acute bacterial skin and skin structure infections (ABSSSI)
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Community acquired pneumonia (CAP)
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
6.7. Others
6.7.1. Key market trends, growth factors and opportunities
6.7.2. Market size and forecast, by region
6.7.3. Market share analysis by country
CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION
7.1. Overview
7.1.1. Market size and forecast
7.2. Protein Synthesis Inhibitors
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Wall Synthesis Inhibitors
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drug Class
8.2.3. Market size and forecast, by Pathogen
8.2.4. Market size and forecast, by Indication
8.2.5. Market size and forecast, by Mechanism of Action
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drug Class
8.2.6.1.2. Market size and forecast, by Pathogen
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Mechanism of Action
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drug Class
8.2.6.2.2. Market size and forecast, by Pathogen
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Mechanism of Action
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drug Class
8.2.6.3.2. Market size and forecast, by Pathogen
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Mechanism of Action
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drug Class
8.3.3. Market size and forecast, by Pathogen
8.3.4. Market size and forecast, by Indication
8.3.5. Market size and forecast, by Mechanism of Action
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drug Class
8.3.6.1.2. Market size and forecast, by Pathogen
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Mechanism of Action
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Drug Class
8.3.6.2.2. Market size and forecast, by Pathogen
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Mechanism of Action
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Drug Class
8.3.6.3.2. Market size and forecast, by Pathogen
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Mechanism of Action
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Drug Class
8.3.6.4.2. Market size and forecast, by Pathogen
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Mechanism of Action
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Drug Class
8.3.6.5.2. Market size and forecast, by Pathogen
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Mechanism of Action
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drug Class
8.3.6.6.2. Market size and forecast, by Pathogen
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Mechanism of Action
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drug Class
8.4.3. Market size and forecast, by Pathogen
8.4.4. Market size and forecast, by Indication
8.4.5. Market size and forecast, by Mechanism of Action
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Drug Class
8.4.6.1.2. Market size and forecast, by Pathogen
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Mechanism of Action
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Drug Class
8.4.6.2.2. Market size and forecast, by Pathogen
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Mechanism of Action
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drug Class
8.4.6.3.2. Market size and forecast, by Pathogen
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Mechanism of Action
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Drug Class
8.4.6.4.2. Market size and forecast, by Pathogen
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Mechanism of Action
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Drug Class
8.4.6.5.2. Market size and forecast, by Pathogen
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Mechanism of Action
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drug Class
8.4.6.6.2. Market size and forecast, by Pathogen
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Mechanism of Action
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drug Class
8.5.3. Market size and forecast, by Pathogen
8.5.4. Market size and forecast, by Indication
8.5.5. Market size and forecast, by Mechanism of Action
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drug Class
8.5.6.1.2. Market size and forecast, by Pathogen
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Mechanism of Action
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drug Class
8.5.6.2.2. Market size and forecast, by Pathogen
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Mechanism of Action
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Drug Class
8.5.6.3.2. Market size and forecast, by Pathogen
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Mechanism of Action
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Drug Class
8.5.6.4.2. Market size and forecast, by Pathogen
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Mechanism of Action
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Alkem Laboratories Ltd.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Pfizer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Acurx Pharmaceuticals, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. Basilea Pharmaceutica Ltd
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Cumberland Pharmaceuticals
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Wockhardt Limited.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Paratek Pharmaceuticals Inc
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Nabriva Therapeutics plc
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Innoviva, Inc
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Merck & Co., Inc.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 09. ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 16. ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2022-2032 ($MILLION)
TABLE 17. ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2022-2032 ($MILLION)
TABLE 19. ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY REGION, 2022-2032 ($MILLION)
TABLE 20. ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY REGION, 2022-2032 ($MILLION)
TABLE 21. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 23. ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 24. ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 25. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 26. ANTIMICROBIAL RESISTANCE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 29. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 30. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 31. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 33. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 34. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 36. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 38. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 39. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 40. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 41. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 42. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 44. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 45. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 46. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 47. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 48. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 49. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 50. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 51. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 53. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 54. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 55. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 56. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 57. UK ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 58. UK ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 59. UK ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 60. UK ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 61. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 62. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 63. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 64. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 65. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 66. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 67. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 70. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 71. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 75. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 76. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 77. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 78. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 79. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 80. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 82. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 83. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 84. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 85. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 86. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 87. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 88. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 89. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 91. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 93. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 94. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 95. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 96. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 97. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 101. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 102. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 103. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 104. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 105. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 106. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 107. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 108. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 109. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 110. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 112. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 113. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 114. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 116. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 117. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 118. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 120. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 121. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 122. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 123. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 124. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 125. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 127. ALKEM LABORATORIES LTD.: KEY STRATERGIES
TABLE 128. PFIZER INC.: KEY EXECUTIVES
TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 132. PFIZER INC.: KEY STRATERGIES
TABLE 133. ACURX PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 134. ACURX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 135. ACURX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 136. ACURX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 137. BASILEA PHARMACEUTICA LTD: KEY EXECUTIVES
TABLE 138. BASILEA PHARMACEUTICA LTD: COMPANY SNAPSHOT
TABLE 139. BASILEA PHARMACEUTICA LTD: PRODUCT SEGMENTS
TABLE 140. BASILEA PHARMACEUTICA LTD: PRODUCT PORTFOLIO
TABLE 141. CUMBERLAND PHARMACEUTICALS: KEY EXECUTIVES
TABLE 142. CUMBERLAND PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 143. CUMBERLAND PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 144. CUMBERLAND PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 145. CUMBERLAND PHARMACEUTICALS: KEY STRATERGIES
TABLE 146. WOCKHARDT LIMITED.: KEY EXECUTIVES
TABLE 147. WOCKHARDT LIMITED.: COMPANY SNAPSHOT
TABLE 148. WOCKHARDT LIMITED.: PRODUCT SEGMENTS
TABLE 149. WOCKHARDT LIMITED.: PRODUCT PORTFOLIO
TABLE 150. PARATEK PHARMACEUTICALS INC: KEY EXECUTIVES
TABLE 151. PARATEK PHARMACEUTICALS INC: COMPANY SNAPSHOT
TABLE 152. PARATEK PHARMACEUTICALS INC: PRODUCT SEGMENTS
TABLE 153. PARATEK PHARMACEUTICALS INC: PRODUCT PORTFOLIO
TABLE 154. NABRIVA THERAPEUTICS PLC: KEY EXECUTIVES
TABLE 155. NABRIVA THERAPEUTICS PLC: COMPANY SNAPSHOT
TABLE 156. NABRIVA THERAPEUTICS PLC: PRODUCT SEGMENTS
TABLE 157. NABRIVA THERAPEUTICS PLC: PRODUCT PORTFOLIO
TABLE 158. NABRIVA THERAPEUTICS PLC: KEY STRATERGIES
TABLE 159. INNOVIVA, INC: KEY EXECUTIVES
TABLE 160. INNOVIVA, INC: COMPANY SNAPSHOT
TABLE 161. INNOVIVA, INC: PRODUCT SEGMENTS
TABLE 162. INNOVIVA, INC: PRODUCT PORTFOLIO
TABLE 163. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 164. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 165. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 166. MERCK & CO., INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ANTIMICROBIAL RESISTANCE MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ANTIMICROBIAL RESISTANCE MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN ANTIMICROBIAL RESISTANCE MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL ANTIMICROBIAL RESISTANCE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTIMICROBIAL RESISTANCE MARKET FOR

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings